NCT06774209 Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors
| NCT ID | NCT06774209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Endometrial Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-03-01 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective exploratory study to explore the application value of gallium 68 labeled-fibroblast activation protein inhibitor-04 Positron Emission Tomography（68Ga-FAPI-04 PET）imaging in patients with endometrial cancer and compare it with the imaging agent with better imaging effects to study its advantages. After patient enrollment, 68Ga-FAPI-04 Positron Emission Tomography/Computed Tomography（PET/CT） and Positron Emission Tomography/Magnetic Resonance Imaging（PET/MRI） examinations are performed, with the imaging agent administered intravenously at a dose of 0.02 to 0.04 mCi/Kg×patient weight (Kg), and a whole-body scan is performed 30-60 minutes later, with images processed as usual. Within 1 week before and after the examination, Fluorine18 labeled-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography（18F-FDG PET/CT） is completed, along with medical history collection and necessary laboratory tests. Subsequently, patients undergo surgical resection of the lesion and suspicious metastatic lymph nodes shown by FAPI PET/CT to obtain the corresponding pathological results. Finally, the diagnostic value of all patients in 68Ga-FAPI-04 PET/CT and PET/MR is analyzed and compared with 18F-FDG PET/CT to study the differences in diagnostic efficacy between the two.
Eligibility Criteria
Inclusion Criteria: * 18-70 years old * Obtaining written informed consent * Being able to accept follow-up * Feasible surgery or biopsy to obtain the final result Exclusion Criteria: * Pregnant and lactating female patients * Patients who are difficult to receive further diagnosis and treatment due to their severe condition * Any patients with contraindications to magnetic resonance imaging
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06774209 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774209 currently recruiting?
Yes, NCT06774209 is actively recruiting participants. Contact the research team at 1261152761@qq.com for enrollment information.
Where is the NCT06774209 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06774209 clinical trial?
NCT06774209 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.